Internal Medicine, Endocrinology, Diabetes, & Metabolism · Texarkana, TX
NPI
1114911369
Since 2005
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
2
Medicare group memberships
Hospitals
4
Hospital affiliations
2602 Saint Michael Dr Ste 201b
Texarkana, TX, 75503
Phone (903) 614-5530
Groups this clinician bills Medicare through
Medicare paid, 2024
$67K
1,255 services
Medicare patients, 2024
576
Average age 72
Drug cost, 2024
$4.2M
9,254 prescriptions
Company payments, 2025
$123
From 5 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Igor E Matwijiw was code 99213 (office e&m - established), 524 times for 369 patients. In total Igor E Matwijiw billed 1,255 services in 8 codes, and Medicare paid $67K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-06-22.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Facility | 524 | 369 | $44.10 | $23K |
| 99214 Office E&M - Established | Facility | 457 | 299 | $66.59 | $30K |
| 99204 Office E&M - New | Facility | 110 | 110 | $91.80 | $10K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 101 | 96 | $12.13 | $1,225 |
| 99203 Office E&M - New | Facility | 38 | 38 | $49.97 | $1,899 |
| 99212 Office E&M - Established | Facility | 23 | 22 | $23.05 | $530 |
By year: 2022 $69K for 1,277 services; 2023 $71K for 1,229 services; 2024 $67K for 1,255 services.
Lab tests billed to Medicare, 2023
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 83036 Blood Count | 32 | 32 | $9.52 | $305 |
Medicare prescription drug claims, 2024
In 2024, the drug Igor E Matwijiw prescribed most often to Medicare patients was Ozempic (Semaglutide), with 1,056 prescriptions and refills. In total Igor E Matwijiw wrote 9,254 Medicare prescriptions that cost $4.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 1,056 | 1,431 | 186 | $1.3M |
| Levothyroxine Sodium Generic | 628 | 1,360 | 159 | $5,355 |
| Jardiance Empagliflozin | 591 | 893 | 120 | $498K |
| Mounjaro Tirzepatide | 444 | 476 | 65 | $498K |
| Farxiga Dapagliflozin Propanediol | 419 | 617 | 80 | $339K |
| Glipizide Generic | 346 | 759 | 94 | $2,309 |
| Glimepiride Generic | 333 | 828 | 106 | $2,999 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 296 | 549 | 78 | $40K |
| Metformin Hcl Generic | 284 | 698 | 74 | $2,968 |
| Tresiba Flextouch U-200 Insulin Degludec | 269 | 418 | 59 | $231K |
| Novolog Flexpen Insulin Aspart | 264 | 446 | 69 | $54K |
| Rosuvastatin Calcium Generic | 212 | 537 | 60 | $1,836 |
| Atorvastatin Calcium Generic | 187 | 461 | 48 | $1,538 |
| Tresiba Flextouch U-100 Insulin Degludec | 185 | 320 | 58 | $120K |
| Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog | 178 | 309 | 41 | $150K |
Brand drugs: 5,502 claims; generic drugs: 3,247 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Igor E Matwijiw $123 ($123 in general payments such as food, travel and fees) from 5 companies. The largest payer was Novo Nordisk Inc with $36.11.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.